Chapter PDF
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Bacigalupo A, Bruno B, Saracco P et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT Working Party. Blood 2000;95:1931–34
Ball SE. The modern management of severe aplastic anaemia. Br J Haematol 2000;110:41–53
Brodsky RA, Jones RJ. Aplastic anaemia. Lancet 2005;365:1647–56
Davies JK, Guinan EC. An update on the management of severe idiopathic aplastic anaemia in children. Br J Haematol 2007;136:549–64
Geroges GE, Storb R. Stem cell transplantation for aplastic anemia. Int J Hematol 2002;75:141–6
Kojima S, Hibi S, Kosaka Y et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporin, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood 2000;96:2049–54
Marsh JCW, Ball SE, Darbyshire P et al. British Committee for Standards in Hematology (BCSH). Guidelines for the diagnosis and management of acquired aplastic anemia. Br J Haematol 2003;123:782–90
Yamaguchi H, Calado RT, Ly H et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 2005;352:1413–24
Young NS. Immunosuppressive treatment of acquired aplastic anemia and immune-mediated bone marrow failure syndromes. Int J Hematol 2002;75:129–40
http://www.aamds.org/ AA and MDS Foundation
http://www.fanconi.org/ Fanconi Anemia Research Fund
Berliner N, Horwitz M, Loughran TP Jr. Congenital and acquired neutropenia. Hematology (ASH Educ Program) 2004:63–79
Boxer LA, Newburger PE. A molecular classification of congenital neutropenia syndromes. Pediatr Blood Cancer 2007;49:609–14
Lakshman R, Finn A. Neutrophil disorders and their management. J Clin Pathol 2001;54:7–19
Manny N, Zelig O. Laboratory diagnosis of autoimmune cytopenias. Curr Opin Hematol 2000;7:414–9
Palmblad JE, von dem Borne AE. Idiopathic, immune, infectious and idiosyncratic neutropenias. Semin Hematol 2002;39:113–20
Welte G, Zeidler C, Dole DC. Severe congenital neutropenia. Semin Hematol 2006;43:189–95
http://www.rarediseases.org/ NORD, Rare Disorders
http://www.nlm.nih.gov/medlineplus/ency/article/001295.htm Medline Plus article
http://www.mascc.org MASCC, Supportive Care
http://www.neutropenia.ca/ Neutropenia Support Assoc
http://www.emedicine.com/med/topic82.htm E-medicine
Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007;357:580–7
Bolton-Maggs PHB, Chalmers EA, Collins PW et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006;135:603–33
Cines DB, Bussel JB, McMillan RB et al. Congenital and acquired thrombocytopenia. Hematology (ASH Educ Program) 2004:390–406
Deutsch VR, Tomer A. Megakaryocyte development and platelet production: Br J Haematol 2006; 134:453–66
Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004;103:390–8
Geddis AE, Kaushansky K. Inherited thrombocytopenias: toward a molecular understanding of disorders of platelet production. Curr Opin Pediatr 2004;16:15–22
George JN. Platelets. Lancet 2000;355:1531–9
Jelic S, Radulovic S. Chemotherapy-associated thrombocytopenia. Ann J Cancer 2006;5:371–82
http://www.pdsa.org Platelet Disorder Support Assoc
http://www.med.unc.edu/isth/ ISTH, Intl Soc Thromb Hemostasis
http://www.nlm.nih.gov/medlineplus/ency/ article/000586.htm MedlinePlus
http://www.emedicine.com/med/topic3480.htm E-medicine
http://marrowfailure.cancer.gov/AMEGA.html NCI, Marrow Failure Disorders
Andemariam B, Bussel J. New therapies for ITP. Curr Opin Hematol 2007;14:427–31
British Committee for Standards in Hematology (BCSH). Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and pregnancy. Br J Haematol 2003;120:574–96
Bussel JB, Kuter DJ, George JN et al. AMG 531, a thrombopoiesis stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672–81
Cines DB, McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med 2005;56:425–42
George JN, Woolf SH, Raskob GE. Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults. American Society of Hematology. Ann Med 1998;30:38–44
McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 2004;104:956–60
Portielle JEA, Westendorp RGJ, Kluin-Nelemans et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549–54
Stasi R, Stipa E, Masi M et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995;98:436–42
http://www.pdsa.org/ PDSA
http://www.emedicine.com/EMERG/topic282.htm E-medicine
http://www.emedicine.com/med/topic1151.htm E-medicine
http://www.scripps.edu/itp/ Scripps Clinic
http://www.itpsupport.org.uk ITP Support Assoc
Alving BM. How I treat heparin-induced thrombopenia and thrombosis. Blood 2003;101:31–7
Arepally GM, Ortel TL. Hepanin-induced thrombocytopenia. N Engl J Med 2006;355:809–17
Keeling D, Davidson S, Watson H. British Committee for Standards in Haematology. The management of heparin-induced thrombocytopenia. Br J Haematol 2006;133:259–69
Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000;96:182–7
Rice L, Attisha WK, Drexler A et al. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002;136:210–5
http://www.med.unc.edu/isth/welcome Intl Soc Thrombosis Hemostasis
http://www.tigc.org/eguidelines/hit05.htm TIGC, Guidelines
Allford SL, Hunt BJ, Rose P et al. British Committee for Standards in Haematology. Guidelines on the diagnosis and management of the thrombotic microangiopathic purpura. Br J Haematol 2003;120:556–73
George JN. Thrombotic thrombocytopenic purpura. N Engl J Med 2006;354:1927–35
Ho VT, Cutler C, Carter S et al. Blood and Marrow Transplant Clinical Trials Network Toxicity Committee Consensus Summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:571–5
Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood 2005;106:11–17
Plaimauer B, Zimmermann K, Volkel D et al. Cloning, expression and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 2002;100:3626–32
Richards A, Goodship JA, Goodship THJ. The genetics and pathogenesis of HUS and TTP. Curr Opin Nephrol Hypertens 2002;11:431–5
Sadler JE, Moake JL, Miyata T et al. Recent advances in thrombotic thrombocytopenic purpura. Hematology (ASH Educ Program) 2004:407–23
Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uremic syndrome. Lancet 2005;365:1073–86
http://moon.ouhsc.edu/jgeorge/TTP.html TTP-HUS Registry
http://www.emedicine.com/emerg/topic579.htm TTP, E-medicine
http://www.emedicine.com/emerg/topic238.htm HUS, E-medicine
http://www.psbc.org/bulletins/bulletin_v7_n2.pdf Puget Sound Blood Center
http://www.crttp.org/ TTP Foundation
http://www.nlm.nih.gov/medlineplus/ency/article/000552.htm MedlinePlus
http://www.nlm.nih.gov/medlineplus/ency/article/000510.htm MedlinePlus
Birgegard G, Aapro MS, Bokemeyer C et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 2005;68(suppl 1):3–11
Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201–16
British Committee for Standards in Hematology (BCSH). Guidelines for the clinical use of red cell transfusion. Br J Haematol 2001;113:24–31
Littlewood TJ. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 2001;28(suppl 8):49–53
Provan D, Weatherall D. Red cells I: inherited anaemias. Lancet 2000;355:1169–75
Provan D, Weatherall D. Red cells II: acquired anemias and polycythaemia. Lancet 2000;355:1260–8
Rizzo JD, Somerfield MP, Hagerty KL et al. ASH/ASCO 2007 clinical practice guideline update on the use of epoetin and darbepoetin. Blood 2007;111:x–y
http://www.anemiainstitute.org/ Anemia Institute
http://www.guideline.gov/ Guideline Clearinghouse
http://www.nlm.nih.gov/medlineplus/anemia.html MedlinePlus
http://www.anemia.org Anemia Action Council
Donovan A, Andrews NC. The molecular regulation of iron metabolism. Hematol J 2004;5:373–80
Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000;96:823–33
Littlewood TJ. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 2001;28(2 suppl 8):49–53
Means RT. Advances in the anemia of chronic disease. Int J Hematol 1999;70:7–12
Thomas C, Thomas L. Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol 2005;11:14–23
Umbreit J. Iron deficiency. Am J Hematol 2005;78:435–43
Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011–23
Zimmermann MB, Hurrell RF. Nutritional iron deficiency. Lancet 2007;370:511–20
http://www.nlm.nih.gov/medlineplus/ency/article/000565.htm Medline Plus
http://www.nlm.nih.gov/medlineplus/ency/article/000584.htm Medline Plus
http://www.umm.edu/blood/aneiron.htm Univ Maryland
http://www.emedicine.com/med/topic1188.htm E-medicine
Dharmarajan TS, Norkus EP. Approaches to vitamin B12 deficiency. Early treatment may prevent devastating complications. Postgrad Med 2001;110:99–105
Fenech M. The role of folic acid and vitamin B12 in genomic stability of human cells. Mutat Res 2001;475:57–67
Provan D, Weatherall D. Red cells II: acquired anaemias and polycythaemia. Lancet 2000;355:1260–8
Toh BH, van Driel IR, Gleeson PA. Pernicious anemia. N Engl J Med 1997;337:1441–8
Wickramashinghe SN. The wide spectrum and unresolved issues of megaloblastic anemia. Semin Hematol 1999;36:3–18
Zittoun J, Zittoun R. Modern clinical testing strategies in cobalamin and folate deficiency. Semin Hematol 1999;36:35–46
http://www.nlm.nih.gov/medlineplus/ency/article/000567.htm Medline Plus
http://web.indstate.edu/thcme/mwking/vitamins.html Introduction to Vitamins
http://www.umm.edu/blood/aneper.htm Univ Maryland
http://www.emedicine.com/MED/topic1420.htm E-medicine
http://www.ashimagebank.org ASH Image Bank
Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol 2007;138:291–304
British Committee for Standards in Haematology. Guidelines for the diagnosis and management of hereditary spherocytosis. Br J Haematol 2004;126:455–74
Gallagher PG. Hereditary elliptocytosis: spectrin and protein 4.1R. Semin Hematol 2004;41:142–64
Gertz A. Management of cold haemolytic syndrome. Br J Haematol 2007;138:422–9
Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in PNH N Engl J Med 2006;355:1233–43
King KE, Ness PM. Treatment of autoimmune hemolytic anemia. Semin Hematol 2005;42:131–6
Mehta A, Mason PJ, Vulliamy TJ. Glucose-6-phosphate dehydrogenase deficiency. Baillieres Best Pract Res Clin Haematol 2000;13:21–38
Stuart MJ, Nagel RL. Sickle-cell disease. Lancet 2004;364:1343–60
http://www.nlm.nih.gov/medlineplus/ency/article/000571.htm Medline Plus
http://www.nlm.nih.gov/medlineplus/ency/article/000534.htm Medline Plus
http://www.umm.edu/blood/anehemol.htm Univ Maryland
http://www.fpnotebook.com/HEM50.htm Family Practice
http://www.emedicine.com/med/topic979.htm E-medicine
Eckardt KU. Pathophysiology of renal anemia. Clin Nephrol 2000;53(1 suppl):S2–8
Eschbach JW. Current concepts of anemia management in chronic renal failure: impact of NKF-DOQI. Semin Nephrol 2000;20:320–9
MacDougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol 2000;20:375–81
Ritz E, Schwenger V. The optimal target hemoglobin. Semin Nephrol 2000;20:382–6
Valderrabano F. Quality of life benefits of early anaemia treatment. Nephrol Dial Transplant 2000;15(suppl 3):23–8
http://www.kidney.org/professionals/doqi/doqi/ doqianemia.html National Kidney Foundation Guidelines
http://www.anemiainstitute.org/ Anemia Institute
http://www.asn-online.com/ American Society of Nephrology
Baglin T, Barrowcliffe TW, Cohen A et al. Guidelines on the use and monitoring of heparin. Br J Haematol 2006;133:19–34
Dahlback B. Blood coagulation. Lancet 2000;355:1627–32
Falanga A. Tumor cell prothrombotic properties. Haemostasis 2001;31(suppl 1):1–4
Manucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004;104:1243–52
Petralia GA, Lemoine NR, Kakkar AK. Mechanisms of disease: the impact of antithrombotic therapy in cancer patients. Nat Clin Pract Oncol 2005;2:356–63
http://www.med.unc.edu/isth/welcome ISTH
http://tollefsen.wustl.edu/projects/coagulation/coagulation.html Washington Univ
http://www.indstate.edu/thcme/mwking/blood-coagulation.html Indiana State Univ
http://www.nlm.nih.gov/medlineplus/ency/article/001304.htm Medline Plus
Dahlback B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med 2005;257:209–23
Delgado J, Jimenez-Yuste V, Hernandez-Navarro F et al. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003;121:21–35
Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752–63
Li T, Chang CY, Jin DY et al. Identification of the gene for vitamin K epoxide reductase. Nature 2004;427:541–4
Wiestner A, Cho HJ, Asch AS et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002;100:3426–8
Zeitler H, Ulrich-Merzenich G, Hess L et al. Treatment of acquired hemophilia by the Bonn-Malmö protocol. Blood 2005;105:2287–93
http://www.med.unc.edu/isth/welcome Intl Soc Thrombosis Hemostasis
http://www.ctds.info/vitamink.html Vitamin K Deficiency
http://www.emedicine.com/med/topic2385.htm E-Medicine
http://www.nlm.nih.gov/medlineplus/ency/ article/002407.htm Medline Plus
Berntorp E. Immune tolerance induction: recombinant vs. human-derived product. Haemophilia 2001;7:109–13
Bolton-Maggs P, Pasi KJ. Haemophilia A and B. Lancet 2003;361:1801–9
Evatt BL, Farrugia A, Shapiro AD et al. Haemophilia 2002: emerging risks of treatment. Haemophilia 2002;8:221–9
Graw J, Brackmann HH, Oldenburg J et al. Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet 2005;6:488–501
Kubisz P, Stasko J. Recombinant activated factor VII in patients at high risk of bleeding. Hematology 2004;9:317–32
Srivastava A. Dose and response in haemophilia: optimization of factor replacement therapy. Br J Haematol 2004;127:12–25
Van den Berg HM, Fischer K, van der Bom JG. Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia 2003;9:27–31
http://www.haemophilia-forum.org Haemophilia Forum
http://www.hemophilia.org Natl Hemophilia Foundation
http://www.haemophilia.org.uk Haemophilia Society
http://www.wfh.org World Fed Hemophilia
http://www.nlm.nih.gov/medlineplus/hemophilia.html Medline Plus
http://med.unc.edu/isth/welcome International Society of Thrombosis and Hemostasis
Berntorp E, Astermark J, Björkman S et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003;9(suppl 1):1–4
Bolton-Maggs P, Pasi KJ. Haemophilia A and B. Lancet 2003;361:1801–9
Di Michele D. Inhibitor development in haemophilia B. Br J Haematol 2007;138:305–15
Kubisz P, Stasko J. Recombinant activated factor VII in patients at high risk of bleeding. Hematology 2004;9:317–32
Srivastava A. Dose and response in haemophilia: optimization of factor replacement therapy. Br J Haematol 2004;127:12–25
Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2005;CD003429
Van den Berg HM, Fischer K, van der Bom JG. Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia 2003;9:27–31
http://www.kcl.ac.uk/ip/petergreen/haemBdatabase.html Hemophilia B Database
http://www.haemophilia-forum.org Haemophilia Forum
http://www.hemophilia.org Natl Hemophilia Foundation
http://www.haemophilia.org.uk Haemophilia Society
http://www.wfh.org World Fed Hemophilia
http://www.nlm.nih.gov/medlineplus/hemophilia.html Medline Plus
http://med.unc.edu/isth/welcome International Society of Thrombosis and Hemostasis
Battle J, Noya MS, Giangrande P et al. Advances in the therapy of von Willebrand disease. Haemophilia 2002;8:301–7
Ginsburg D. Molecular genetics of von Willebrand disease. Thromb Haemost 1999;82:585–91
Manucci PM. Treatment of von Willebrand’s disease. N Engl J Med 2004;351:683–94
Rodeghiero F, Castaman G. Treatment of von Willebrand disease. Semin Hematol 2005;42:29–35
Ruggeri ZM. Developing basic and clinical research on von Willebrand factor and von Willebrand disease. Thromb Haemost 2000;84:147–9
Sadler JE, Mannucci PM, Berntorp E et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000;84:160–74
Schneppenheim R, Budde U. Phenotypic and genotypic diagnosis of von Willebrand disease: a 2004 update. Semin Hematol 2005;42:15–28
http://www.shef.ac.uk/vwf/ ISTH VWF Database
http://www.allaboutbleeding.com/ VWD Resource
http://www.nlm.nih.gov/medlineplus/ency/ article/000544.htm VWD, Medline Plus
http://www.hemophilia.org/bdi/bdi_types3.htm Hemophilia Foundation
www.wfh.org World Fed Hemophilia
www.hemophilia.ca/en/2.2.php Canadian Hemophilia Soc
www.emedicine.com/med/topic2392.htm E-Medicine
Bernard GR, Vincent JH, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709
De Cicco M. The prothrombotic state in cancer: pathogenetic mechanisms. Crit Rev Hematol Oncol 2004;50:187–96
Franchini M, Manzato F. Update on the treatment of disseminated intravascular coagulation. Hematology 2004;9:81–5
Levi M. Disseminated intravascular coagulation: what’s new? Crit Care Clin 2005;21:449–67
Toh CH, Dennis M. DIC 2002: a review of disseminated intravascular coagulation. Hematology 2003;8:65–71
Warren BL, Reid A, Singer P et al. High dose antithrombin III in severe sepsis. JAMA 2001;286:1869–78
Yanada M, Matsushita T, Suzuki M et al. DIC in acute leukemia: clinical and laboratory features at presentation. Eur J Haematol 2006;77:282–7
http://www.med.unc.edu/isth/ Intl Soc Thromb Haemost
http://www.nlm.nih.gov/medlineplus/ency/article/000573.htm Medline Plus
http://www.emedicine.com/med/topic577.htm E-medicine
Baglin IP, Cousins D, Keeling DM et al. Recommendations from the British Committee for Standard in Haematology and National Patient Safety Agency. Br J Haematol 2006;136:26–9
British Committee for Standards in Haematology (BCSH). Guideline. Investigation and management of heritable thrombophilia. Br J Haematol 2001;114:512–28
Francis CW. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl Med 2007;356:1438–44
Klerk CPW, Smorenburg SM, Otten HM et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130–5
Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005;365:1163–74
Lee AYY, Rickles FR, Julian JA et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123–9
Lopez JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology (ASH Educ Program) 2004;439–56
Lyman GH, Khorana AA, Falanga A et al. ASCO Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:x–y
http://www.nlm.nih.gov/medlineplus/ency/article/000156.htm Medline Plus
http://www.emedicine.com/emerg/topic122.htm E-Medicine
http://www.med.unc.edu/isth ISTH
http://www.tri-london.ac.uk/ Thrombosis Res Inst
http://www.tigc.org TIGC
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Finke, J. et al. (2008). Hematology and Hemostasis. In: Berger, D., Engelhardt, M., Henß, H., Mertelsmann, R. (eds) Concise Manual of Hematology and Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-73277-8_6
Download citation
DOI: https://doi.org/10.1007/978-3-540-73277-8_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-73276-1
Online ISBN: 978-3-540-73277-8
eBook Packages: MedicineMedicine (R0)